A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice

Janíková, Andrea; Marečková, Andrea; Dvořáková, Dana; Bortlíček, Zbyněk; Tichý, Boris; Navrátil, Milan; Král, Zdeněk; Pospı́šilová, Šárka; Mayer, Jiřı́

doi:10.1016/j.exphem.2012.02.005

Cited by 3 publications

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,11,12 Although it has been demonstrated across various treatment modalities that conversion to Bcl-2/IgH negativity in FL results in prolonged progression-free survival (PFS) and overall survival, [13][14][15][16] the prognostic value of pre-and posttreatment Bcl-2/IgH levels from either BM or PB are still discussed controversially. 4,7,17 Several confounding factors contributing to this controversy include assay sensitivity, sample source, patient population, and evolving treatment modalities. Standard chemotherapy does not achieve disease eradication from the PB or BM in the majority of patients, 7,10,14,15 whereas rituximab as single agent or in combination with chemotherapy leads to a complete clearance of Bcl-2/IgH-positive cells in most patients, 5,18 indicating that Bcl-2/IgH levels in PB are strongly affected by rituximab use.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Zohren

Bruns

Pechtel

et al. 2015

Blood

View full text Add to dashboard Cite

Key Points• Independent prognostic relevance of quantitative Bcl-2/IgH monitoring in the PB of patients with FL before and after first-line therapy.Bcl-2/IgH rearrangements can be quantified in follicular lymphoma (FL) from peripheral blood (PB) by polymerase chain reaction (PCR No PFS difference between treatment arms was observed in Bcl-2/IgH-positive patients. A positive posttreatment Bcl-2/IgH status was associated with shorter PFS (8.7 months vs not reached; HR, 3.15; 95% CI, 1.51-6.58; P 5 .002). By multivariate analysis, the pretreatment Bcl-2/IgH level was the strongest predictor for PFS. Our data suggest that pre-and posttreatment Bcl-2/IgH levels from PB have significant prognostic value for PFS in FL patients receiving first-line immunochemotherapy. This trial was

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Zohren

Bruns

Pechtel

et al. 2015

Blood

View full text Add to dashboard Cite

show abstract

Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

Gao

Zhang²,

Liu³

et al. 2022

Ann Hematol

View full text Add to dashboard Cite

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?

Janíková

Bortlíček

Campr

et al. 2015

Leukemia & Lymphoma

View full text Add to dashboard Cite

Early-stage follicular lymphoma (FL) has traditionally been treated with involved-field radiotherapy (RT). Rituximab (R) is a low-toxic, efficient systemic therapy for FL, but there are no data about its clinical impact in early FL. We retrospectively analyzed 93 patients with stage I-II indolent FL treated with RT (n=65) or RT+R (n=14) or R alone (n=14). Median follow-up was 5.0 years for patients with RT, 2.8 years for the RT+R subgroup and 2.5 years for patients treated with R. The complete response rate was 92%, 100% and 86% (not significant) and the median PFS was 3.3 years, not reached and 4.9 years (p=0.035) for the RT, RT+R and R arms, with no impact on overall survival. R combined with RT seems to give better results in terms of global FL control, but longer follow-up and prospective comparison are needed to verify these results.

show abstract

A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice

Cited by 3 publications

References 47 publications

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy

Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis

Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?

Contact Info

Product

Resources

About